Nitric oxide and pancreatic cancer pathogenesis, prevention, and treatment

Current Pharmaceutical Design

Volumn 16, Issue 4, 2010, Pages 421-427

  Wang, Liwei ^a   Xie, Keping ^b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Metastasis; NO; Pancreas; Prevention; Progression; Signaling pathway; Treatment

Indexed keywords

ETOPOSIDE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE ACETYLSALICYLIC ACID; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NITRIC OXIDE DONOR; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; CHEMOPROPHYLAXIS; CYTOTOXICITY; EPIGENETICS; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; METASTASIS; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; DRUG POTENTIATION; METABOLISM;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; DRUG SYNERGISM; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77949461469     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790232194     Document Type: Review

References (81)

1. American Cancer Society. Statistics for 2009. www.cancer.org
2. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005; 31: 301-16.
3. Kuvshinoff BW, Bryer MP. Treatment of resectable and locally advanced pancreatic cancer. Cancer Control 2000; 7: 428-36.
4. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004; 5: 541-9.
5. Sohn TA, Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 2000; 9: 95-101.
6. Sakorafas GH, Tsiotos GG. Molecular biology of pancreatic cancer: potential clinical implications. BioDrugs 2001; 15: 439-52.
7. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-72.
8. Kern SE. Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am 2000; 84: 691-5.
9. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54.
10. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-4.
11. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003; 2: 8.
12. Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004; 15: 297-324.
13. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 2003; 34: 969-86.
14. Lancaster JR Jr, Xie K. Tumors face NO problems? Cancer Res 2006; 66: 6459-62.
15. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008; 19: 217-24.
16. Hirst DG, Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007; 12: 3406-18.
17. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in tumor angiogenesis. Cancer Treat Res 2004; 117: 155-67.
18. Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase activity and amino nitrogen to nitrate. Science 1987; 235: 473-476.
19. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006; 8: 1329-37.
20. Radomski MK, Jenkins DC, Holmes L, Moncada S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 1991; 51: 6073-6077.
21. Moochhala S, Chhatwal VJ, Chan ST, Ngoi SS, Chia YW, Rauff A. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996; 17: 1171-4.
22. Martin JH, Alalami O, van den Berg HW. Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence. Cancer Lett 1999; 144: 65-74.
23. Jessup JM, Battle P, Waller H, Edmiston KH, Stolz DB, Watkins SC, et al. Reactive nitrogen and oxygen radicals formed during hepatic ischemia-reperfusion kill weakly metastatic colorectal cancer cells. Cancer Res 1999; 59: 1825-9.
24. Yim CY, Bastian NR, Smith JC, Hibbs JB Jr, Samlowski WE. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res 1993; 53: 5507-11.
25. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994; 91: 9407-11.
26. Pipili-Synetos E, Papageorgiou A, Sakkoula E, Sotiropoulou G, Fotsis T, Karakiulakis G, et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116: 1829-34.
27. Rocha M, Kruger A, Van Rooijen N, Schirrmacher V, Umansky V. Liver endothelial cells participate in T-cell-dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo. Int J Cancer 1995; 63: 405-11.
28. Umansky V, Rocha M, Schirrmacher V. Liver endothelial cells: participation in host response to lymphoma metastasis. Cancer Metastasis Rev 1996; 15: 273-9.
29. Yamamoto T, Terada N, Seiyama A, Nishizawa Y, Akedo H, Kosaka H. Increase in experimental pulmonary metastasis in mice by L-arginine under inhibition of nitric oxide production by NG-nitro-L-arginine methyl ester. Int J Cancer 1998; 75: 140-4.
30. Wei D, Richardson EL, Zhu K, Wang L, Le X, He Y, et al. Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res 2003; 63: 3855-9.
31. Shi Q, Xiong Q, Wang B, Le X, Khan NA, Xie K. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res 2000; 60: 2579-83.
32. Wang B, Xiong Q, Shi Q, Le X, Abbruzzese JL, Xie K. Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res 2001; 61: 71-5.
33. Wang B, Xiong Q, Shi Q, Le X, Xie K. Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene 2001; 20: 6930-7.
34. Gansauge S, Nussler AK, Beger HG, Gansauge F. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 1998; 9: 611-7.
35. Nussler AK, Gansauge S, Gansauge F, Fischer U, Butzer U, Kremsner PG, et al. Overexpression of endothelium-derived nitric oxide synthase isoform 3 in the vasculature of human pancreatic tumor biopsies. Langenbecks Arch Surg 1998; 383: 474-80.
36. Vickers SM, MacMillan-Crow LA, Green M, Ellis C, Thompson JA. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg 1999; 134: 245-51.
37. Kong G, Kim EK, Kim WS, Lee YW, Lee JK, Paik SW, et al. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer. Int J Pancreatol 2001; 29: 133-40.
38. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, et al. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 2002; 17: 914-21.
39. Kasper HU, Wolf H, Drebber U, Wolf HK, Kern MA. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density. World J Gastroenterol 2004; 10: 1918-22.
40. Franco L, Doria D, Bertazzoni E, Benini A, Bassi C. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat 2004; 73: 51-8.
41. Wang B, Shi Q, Abbruzzese JL, Xiong Q, Le X, Xie K. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Pancreatol 2001; 29: 37-46.
42. Wang B, Wei D, Crum VE, Richardson EL, Xiong HH, Luo Y, et al. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 2003; 22: 1771-82.
43. Le X, Wei D, Huang S, Lancaster JR Jr, Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci USA 2005; 102: 8758-63.
44. Gansauge S, Nussler AK, Beger HG, Gansauge F. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 1998; 9: 611-7.
45. Hajri A, Metzger E, Vallat F, Coffy S, Flatter E, Evrard S, et al. Role of nitric oxide in pancreatic tumor growth: in vivo and in vitro studies. Br J Cancer 1998; 78: 841-9.
46. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997; 11: 443-448.
47. Brune B. Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 2003; 10: 864-869.
48. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 2009; 16: 130-43.
49. Le Bitoux MA, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol 2008; 130: 1079-90.
50. Kuper H., Adami HO, Trichopoulos, D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-183.
51. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
52. Macarthur M, Hold GL, El Omar EM. Inflammation and cancer II: role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004; 286: G515-G520.
53. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
54. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
55. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 2006; 387: 365-372.
56. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005; 15: 277-289.
57. Ohshima H. Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. Toxicol Lett 2003; 140-141: 99-104.
58. Ohshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 2005; 591, 110-122.
59. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001; 281: 626-G634.
60. Tamir S, Rojas-Walker T, Wishnok JS, Tannenbaum SR. DNA damage and genotoxicity by nitric oxide. Methods Enzymol 1996; 269: 230-243.
61. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry 1998; 63: 854-865.
62. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1-40.
63. Hold GL, El-Omar EM Genetic aspects of inflammation and cancer. Biochem J 2008; 410: 225-235.
64. Jackson L, Evers BM. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 2006; 130: 39-65.
65. MacFarlane AJ, Stover PJ. Convergence of genetic, nutritional and inflammatory factors in gastrointestinal cancers. Nutr Rev 2007; 65: S157-66.
66. Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005; 5: 514-29.
67. Sawa T, Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 2006; 14: 91-100.
68. DiMagno MJ. Nitric oxide pathways and evidence-based perturbations in acute pancreatitis. Pancreatology 2007; 7: 403-8.
69. Xiong Q, Shi Q, Le X, Wang B, Xie K. Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2001; 21: 529-37.
70. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002; 303: 1273-82.
71. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans 2007; 35: 1364-8.
72. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 2006; 66: 4503-11.
73. Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans 2005; 33: 701-4.
74. Bruns CJ, Shinohara H, Harbison MT, Davis DW, Nelkin G, Killion JJ, et al. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res 2000; 60: 2-7.
75. Verovski VN, Van den Berge DL, Soete GA, Bols BL, Storme GA. Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer 1996; 74: 1734-42.
76. Thomas WJ, Thomas DL, Knezetic JA, Adrian TE. The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells. Pancreas 2002; 24: 161-8.
77. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004; 64: 1331-7.
78. Müerköster SS, Lust J, Arlt A, Häsler R, Witt M, Sebens T, et al. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 2006; 25: 3973-81.
79. Borradaile NM. and Pickering, J. G. NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des 2009; 15(1): 110-7.
80. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009; 15(7): 792-808.
81. Martin-Padura I, Bertolini F. The circulating endothelial cell in cancer: towards marker and target identification. Curr Pharm Des 2008; 14(36): 3780-9.